{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:41:51Z","timestamp":1789180911825,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00210-025-04259-9","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T23:45:35Z","timestamp":1747352735000},"page":"14603-14616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factor XI\/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation with stroke risk: a GRADE-assessed meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"398","author":[{"given":"Ahmed","family":"Emara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Farid","family":"Gadelmawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Emara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2875","authenticated-orcid":false,"given":"Mohamed S.","family":"Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ellebedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Hemmeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Aldemerdash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Abduljalil","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basel","family":"Abdelazeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"6","key":"4259_CR1","doi-asserted-by":"publisher","first-page":"151484","DOI":"10.1016\/j.semnephrol.2023.151484","volume":"43","author":"M Ades","year":"2023","unstructured":"Ades M, Simard C, Vanassche T, Verhamme P, Eikelboom J, Mavrakanas TA (2023) Factor XI inhibitors: potential role in end-stage kidney disease. Semin Nephrol 43(6):151484. https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151484","journal-title":"Semin Nephrol"},{"issue":"1","key":"4259_CR2","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.rpth.2025.102689","volume":"9","author":"MA Al Sharif","year":"2025","unstructured":"Al Sharif MA, Mathews N, Tasneem S, Moffat KA, Carlino SA, Mithoowani S, Hayward CPM (2025) Measurement of factor XIII for diagnosis and management of deficiencies: insights from a retrospective review of ten years of data on consecutive samples and patients. Res Pract Thromb Haemost 9(1):102689","journal-title":"Res Pract Thromb Haemost"},{"key":"4259_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jacc.2023.12.003","volume":"83","author":"F Andreotti","year":"2024","unstructured":"Andreotti F, Massetti M, Montalescot G (2024) Thrombosis, bleeding, and the promise of factor XI(a) inhibition. J Am Coll Cardiol 83:679\u2013681","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"4259_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","volume":"40","author":"S Ballestri","year":"2023","unstructured":"Ballestri S, Romagnoli E, Arioli D, Coluccio V, Marrazzo A, Athanasiou A, Di Girolamo M, Cappi C, Marietta M, Capitelli M (2023) Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review. Adv Ther 40(1):41\u201366","journal-title":"Adv Ther"},{"issue":"15","key":"4259_CR5","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood.2023020721","volume":"143","author":"AA Barg","year":"2024","unstructured":"Barg AA, Livnat T, Kenet G (2024) Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment. Blood 143(15):1455\u20131464","journal-title":"Blood"},{"issue":"3","key":"4259_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1405760","volume":"372","author":"HR B\u00fcller","year":"2015","unstructured":"B\u00fcller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 372(3):232\u2013240. https:\/\/doi.org\/10.1056\/NEJMoa1405760","journal-title":"N Engl J Med"},{"issue":"9","key":"4259_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/01.JAA.0000854516.90788.a8","volume":"35","author":"N Canales","year":"2022","unstructured":"Canales N, Cao T, Fakourfar N, Snee M, Tsu L (2022) Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease. JAAPA 35(9):17\u201318","journal-title":"JAAPA"},{"issue":"7\u20138","key":"4259_CR8","first-page":"16799","volume":"134","author":"S Carlin","year":"2024","unstructured":"Carlin S, Jakovac M, Budaj A, Eikelboom J (2024) Factor XI inhibition in cardiovascular disease. Polish Arch Intern Med 134(7\u20138):16799","journal-title":"Polish Arch Intern Med"},{"issue":"10264","key":"4259_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","volume":"396","author":"N Chan","year":"2020","unstructured":"Chan N, Sobieraj-Teague M, Eikelboom JW (2020) Direct oral anticoagulants: evidence and unresolved issues. Lancet 396(10264):1767\u20131776","journal-title":"Lancet"},{"issue":"7","key":"4259_CR10","doi-asserted-by":"publisher","first-page":"euae195","DOI":"10.1093\/europace\/euae195","volume":"26","author":"S Cheng","year":"2024","unstructured":"Cheng S, He J, Han Y, Han S, Li P, Liao H, Guo J (2024) Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021. Europace 26(7):euae195","journal-title":"Europace"},{"issue":"6","key":"4259_CR11","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/hae.12474","volume":"20","author":"T De Jager","year":"2014","unstructured":"De Jager T, Pericleous L, Kokot-Kierepa M, Naderi M, Karimi M (2014) The burden and management of FXIII deficiency. Haemophilia 20(6):733\u2013740","journal-title":"Haemophilia"},{"issue":"3","key":"4259_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1093\/europace\/euac237","volume":"25","author":"X-J Dong","year":"2023","unstructured":"Dong X-J, Wang B-B, Hou F-F, Jiao Y, Li H-W, Lv S-P, Li F-H (2023) Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2019. Europace 25(3):793\u2013803","journal-title":"Europace"},{"issue":"7109","key":"4259_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. bmj 315(7109):629\u2013634","journal-title":"bmj"},{"issue":"6","key":"4259_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jacc.2023.12.004","volume":"83","author":"JW Eikelboom","year":"2024","unstructured":"Eikelboom JW, Mundl H, Alexander JH, Caso V, Connolly SJ, Coppolecchia R, Gebel M, Hart RG, Holberg G, Keller L, Patel MR, Piccini JP, Rao SV, Shoamanesh A, Tamm M, Viethen T, Yassen A, Bonaca MP (2024) Bleeding outcomes in patients treated with asundexian in phase II trials. J Am Coll Cardiol 83(6):669\u2013678. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.004","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4259_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","volume":"21","author":"JC Fredenburgh","year":"2023","unstructured":"Fredenburgh JC, Weitz JI (2023) News at XI: moving beyond factor Xa inhibitors. J Thromb Haemost 21(7):1692\u20131702","journal-title":"J Thromb Haemost"},{"issue":"11","key":"4259_CR16","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1161\/STROKEAHA.119.026545","volume":"50","author":"B Georgi","year":"2019","unstructured":"Georgi B, Mielke J, Chaffin M, Khera AV, Gelis L, Mundl H, van Giezen JJJ, Ellinor P, Kathiresan S, Ziegelbauer K, Freitag DF (2019) Leveraging human genetics to estimate clinical risk reductions achievable by inhibiting factor XI. Stroke 50(11):3004\u20133012. https:\/\/doi.org\/10.1161\/STROKEAHA.119.026545","journal-title":"Stroke"},{"issue":"2","key":"4259_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.23736\/S2724-5683.23.06474-8","volume":"73","author":"A Greco","year":"2025","unstructured":"Greco A, Ammirabile N, Landolina D, Imbesi A, Raffo C, Capodanno D (2025) Future of factor XI inhibitors in cardiovascular practice. Minerva Cardiol Angiol 73(2):201\u2013218. https:\/\/doi.org\/10.23736\/S2724-5683.23.06474-8","journal-title":"Minerva Cardiol Angiol"},{"issue":"8","key":"4259_CR18","doi-asserted-by":"publisher","first-page":"103361","DOI":"10.1016\/j.autrev.2023.103361","volume":"22","author":"S-Y Guan","year":"2023","unstructured":"Guan S-Y, Zheng J-X, Sam NB, Xu S, Shuai Z, Pan F (2023) Global burden and risk factors of musculoskeletal disorders among adolescents and young adults in 204 countries and territories, 1990\u20132019. Autoimmun Rev 22(8):103361","journal-title":"Autoimmun Rev"},{"key":"4259_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.122.061987","volume":"146","author":"YX Gue","year":"2022","unstructured":"Gue YX, Gorog DA, Lip GYH (2022) Factor XIa inhibition: is it a novel alternative antithrombotic strategy for high-risk ACS patients? Circulation 146:1207\u20131209","journal-title":"Circulation"},{"issue":"4","key":"4259_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","volume":"43","author":"A Guha","year":"2022","unstructured":"Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D (2022) Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis. Eur Heart J 43(4):300\u2013312","journal-title":"Eur Heart J"},{"issue":"7650","key":"4259_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"8","key":"4259_CR22","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","volume":"81","author":"J Harrington","year":"2023","unstructured":"Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR (2023) Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week. J Am Coll Cardiol 81(8):771\u2013779. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.057","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"4259_CR23","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1161\/STROKEAHA.115.011139","volume":"46","author":"DT Hayden","year":"2015","unstructured":"Hayden DT, Hannon N, Callaly E, N\u00edChr\u00f3in\u00edn D, Horgan G, Kyne L, Duggan J, Dolan E, O\u2019Rourke K, Williams D (2015) Rates and determinants of 5-year outcomes after atrial Fibrillation\u2013related stroke: a population study. Stroke 46(12):3488\u20133493","journal-title":"Stroke"},{"issue":"1","key":"4259_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-physiol-031720-085307","volume":"83","author":"J Heijman","year":"2021","unstructured":"Heijman J, Linz D, Schotten U (2021) Dynamics of atrial fibrillation mechanisms and comorbidities. Annu Rev Physiol 83(1):83\u2013106","journal-title":"Annu Rev Physiol"},{"key":"4259_CR25","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2024) Cochrane handbook for systematic reviews of interventions, version 6.5 (updated August 2024). Cochrane. https:\/\/training.cochrane.org\/handbook. Accessed Mar 2025"},{"issue":"11","key":"4259_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539\u20131558","journal-title":"Stat Med"},{"key":"4259_CR27","doi-asserted-by":"publisher","unstructured":"Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH (2025) Atrial fibrillation: a review. JAMA 333(4):329\u2013342. https:\/\/doi.org\/10.1001\/jama.2024.22451","DOI":"10.1001\/jama.2024.22451"},{"issue":"6","key":"4259_CR28","first-page":"1157","volume":"35","author":"MD Lewandowska","year":"2021","unstructured":"Lewandowska MD, Connors JM (2021) Factor XI Deficiency Hematol Clin 35(6):1157\u20131169","journal-title":"Factor XI Deficiency Hematol Clin"},{"issue":"Supplement_B","key":"4259_CR29","doi-asserted-by":"publisher","first-page":"B65","DOI":"10.1093\/eurheartjsupp\/suad070","volume":"25","author":"F Muscente","year":"2023","unstructured":"Muscente F, De Caterina R (2023) The new in anticoagulation: factor XI inhibitors. Eur Hear J Suppl 25(Supplement_B):B65\u2013B68","journal-title":"Eur Hear J Suppl"},{"key":"4259_CR30","doi-asserted-by":"publisher","first-page":"903029","DOI":"10.3389\/fcvm.2022.903029","volume":"9","author":"S Nopp","year":"2022","unstructured":"Nopp S, Kraemmer D, Ay C (2022) Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med 9:903029","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"4259_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10(1):89. https:\/\/doi.org\/10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"issue":"9","key":"4259_CR32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11886-024-02100-y","volume":"26","author":"SM Patel","year":"2024","unstructured":"Patel SM, Ruff CT (2024) Will factor XI inhibitors replace current anticoagulants for stroke prevention in atrial fibrillation? Curr Cardiol Rep 26(9):911\u2013917. https:\/\/doi.org\/10.1007\/s11886-024-02100-y","journal-title":"Curr Cardiol Rep"},{"issue":"10333","key":"4259_CR33","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","volume":"399","author":"JP Piccini","year":"2022","unstructured":"Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet (London, England) 399(10333):1383\u20131390. https:\/\/doi.org\/10.1016\/S0140-6736(22)00456-1","journal-title":"Lancet (London, England)"},{"issue":"1","key":"4259_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, Ma C-S, Goodman SG, Oldgren J, Hammett C (2025) Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 392(1):23\u201332","journal-title":"N Engl J Med"},{"issue":"9","key":"4259_CR35","first-page":"1210","volume":"129","author":"M Preis","year":"2017","unstructured":"Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, Saliba W (2017) Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood, J Am Soc Hematol 129(9):1210\u20131215","journal-title":"Blood, J Am Soc Hematol"},{"issue":"4","key":"4259_CR36","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1056\/NEJMoa2406674","volume":"392","author":"CT Ruff","year":"2025","unstructured":"Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, Goodrich EL, Chen S-A, Goodman SG, Joung B (2025) Abelacimab versus rivaroxaban in patients with atrial fibrillation. N Engl J Med 392(4):361\u2013371","journal-title":"N Engl J Med"},{"key":"4259_CR37","doi-asserted-by":"publisher","first-page":"101119","DOI":"10.1016\/j.blre.2023.101119","volume":"62","author":"D Santagata","year":"2023","unstructured":"Santagata D, Donadini MP, Ageno W (2023) Factor XI inhibitors for the prevention of cardiovascular disease: a new therapeutic approach on the horizon? Blood Rev 62:101119. https:\/\/doi.org\/10.1016\/j.blre.2023.101119","journal-title":"Blood Rev"},{"issue":"4","key":"4259_CR38","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/hae.12628","volume":"21","author":"C Santoro","year":"2015","unstructured":"Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, Bochicchio RA, Ferrara G, Guarini A, Fo\u00e0 R, Mazzucconi MG (2015) Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia 21(4):496\u2013501. https:\/\/doi.org\/10.1111\/hae.12628","journal-title":"Haemophilia"},{"key":"4259_CR39","doi-asserted-by":"publisher","unstructured":"Sobral MVS, Queiroz I, Amador WFO, Moreira JL de ML, Pirolla R da C, Menechini RB, Queiroga F, Pacagnelli FL, Guida CM (2025) Efficacy and safety of oral factor XI\/XIa inhibitors in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Hear Rhythm. https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.052","DOI":"10.1016\/j.hrthm.2025.02.052"},{"key":"4259_CR40","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ l4898\u2013l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"4259_CR41","doi-asserted-by":"publisher","unstructured":"Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J (2018) Risks and benefits of direct oral anticoagulants versus warfarin in a real-world setting: cohort study in primary care. BMJ 362:k2505. https:\/\/doi.org\/10.1136\/bmj.k2505","DOI":"10.1136\/bmj.k2505"},{"issue":"2","key":"4259_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2019.20687","volume":"323","author":"JI Weitz","year":"2020","unstructured":"Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, Metzig C, Raskob GE (2020) Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA 323(2):130\u2013139. https:\/\/doi.org\/10.1001\/jama.2019.20687","journal-title":"JAMA"},{"issue":"23","key":"4259_CR43","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","volume":"385","author":"JI Weitz","year":"2021","unstructured":"Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, Mahaffey KW, Notani RS, Roberts R, Segers A, Raskob GE (2021) Milvexian for the prevention of venous thromboembolism. N Engl J Med 385(23):2161\u20132172. https:\/\/doi.org\/10.1056\/NEJMoa2113194","journal-title":"N Engl J Med"},{"key":"4259_CR44","doi-asserted-by":"publisher","unstructured":"Wolfes J, Eckardt L (2024) Die 2024 ESC-Leitlinien zum Management von Vorhofflimmern. Herzschr Elektrophys 35:318\u2013323. https:\/\/doi.org\/10.1007\/s00399-024-01053-7","DOI":"10.1007\/s00399-024-01053-7"},{"issue":"6","key":"4259_CR45","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","volume":"5","author":"X Yao","year":"2016","unstructured":"Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc 5(6):e003725","journal-title":"J Am Heart Assoc"},{"key":"4259_CR46","doi-asserted-by":"publisher","unstructured":"Zeng S, Kaisaier W, Liu C, Zhu W (2025) Factor XI\/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation. Eur J Intern Med. https:\/\/doi.org\/10.1016\/j.ejim.2025.02.013","DOI":"10.1016\/j.ejim.2025.02.013"},{"issue":"22","key":"4259_CR47","first-page":"4684","volume":"116","author":"H Zhang","year":"2010","unstructured":"Zhang H, L\u00f6wenberg EC, Crosby JR, MacLeod AR, Zhao C, Gao D, Black C, Revenko AS, Meijers JCM, Stroes ES (2010) Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood, J Am Soc Hematol 116(22):4684\u20134692","journal-title":"Blood, J Am Soc Hematol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04259-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04259-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T11:14:39Z","timestamp":1761304479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04259-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":47,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["4259"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04259-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}